Microporous Sol-Gel Silica For Enabling Delivery Of Challenging Active Pharmaceutical Ingredients

Time: 4:55 pm - 5:15 pm

Date: 30 April 2019

30-april-2019 16:55 30-april-2019 17:15 Europe/London Microporous Sol-Gel Silica For Enabling Delivery Of Challenging Active Pharmaceutical Ingredients

iCRT (inorganic Controlled Release Technology) is one of Lucideon’s proprietary materials technology platforms. In one manifestation, an active pharmaceutical ingredient (API) is uniformly distributed within a porous silica matrix and employed as a controlled release drug delivery system. Active release rates can be tailored to span from minutes (immediate release) to days (sustained release) by… Read more »

Making Pharmaceuticals

Synopsis

iCRT (inorganic Controlled Release Technology) is one of Lucideon’s proprietary materials technology platforms. In one manifestation, an active pharmaceutical ingredient (API) is uniformly distributed within a porous silica matrix and employed as a controlled release drug delivery system. Active release rates can be tailored to span from minutes (immediate release) to days (sustained release) by careful control of the synthetic and process variables, as determined by the particular application and dosage form. The use of a Design of Experiments (DoE) approach is instrumental in minimizing the cost and time-scales needed to achieve a target release profile.

The carrier particles are made by a sol-gel route which uses mild operating conditions and does not require a post-process calcination. Not only does this makes it a green manufacturing process but also provides additional versatility in release profiles by virtue of adding the active prior to, or during, the sol-gel reactions. By avoiding post-impregnation of the active into a final porous carrier, burst effects are avoided due to preferential active adsorption at the particle surface.

There is a significant need for novel materials technologies to provide solutions for the most challenging drug delivery applications. The presentation will show how iCRT has been used to overcome some of the formulation challenges: the sustained release of highly water soluble compounds, the production of sustained release pharmaceutical dosage forms with abuse deterrent properties and also the controlled release of actives with poor water solubility.

The preparation and use of polymer-iCRT composite materials for active delivery will also be discussed together with different formulations (tablets, spherical beads, monolith…).

Speakers

« Back